eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

3/2023
vol. 15
 
Share:
Share:
abstract:
Original paper

Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation

Tamer Soror
1, 2
,
Corrina Melchert
1
,
Dirk Rades
1
,
Axel S. Merseburger
3
,
György Kovács
4

  1. Radiation Oncology Department, University of Lübeck/UKSH-CL, Lübeck, Germany
  2. National Cancer Institute (NCI), Radiation Oncology Department, Cairo University, Egypt
  3. Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany
  4. Università Cattolica del Sacro Cuore, Gemelli-INTERACTS, Rome, Italy
J Contemp Brachytherapy 2023; 15, 3: 159–165
Online publish date: 2023/06/21
View full text Get citation
 
Purpose:
To report the use of high-dose-rate (HDR) interventional radiotherapy (brachytherapy, IRT) as a salvage treatment for macroscopic histologically confirmed local relapse of prostatic cancer after prostatectomy and subsequent external irradiation.

Material and methods:
A retrospective study of patients with prostate adenocarcinoma, treated with HDR-IRT for an isolated local relapse after prostatectomy and external irradiation at our institution (2010-2020). Treatment results and treatment related-toxicity were recorded. Clinical outcomes were analyzed.

Results:
Ten patients were identified. The median age was 63 years (range, 59-74 years), and the median follow-up time was 34 months (range, 10-68 months). Four patients had a biochemical relapse, and the mean time to prostate specific antigen (PSA) increase was 13 months. One-year biochemical failure-free survival (bFFS), 3-year bFFS, and 4-year bFFS were 80%, 60%, and 60%, respectively. Most of the treatment-related toxicities were grade 1-2. Two patients experienced grade 3 late genitourinary toxicity.

Conclusions:
HDR-IRT seems to be an effective treatment option showing acceptable toxicity for prostate cancer patients with isolated macroscopic histologically confirmed local relapse after prostatectomy and subsequent external irradiation.

keywords:

interventional radiotherapy, high-dose-rate brachytherapy, prostate cancer, biochemical failure

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.